4174.TWOOBI
浩鼎 · Biotech and medical · Taipei Exchange · Taiwan
Four figures
From the exchange's own figures. Each line says what it is based on.
- Revenue growth
- Revenue −31% this year to October 2026, against the same months last year.
- Return on equity
- It earns −97% a year on its shareholders' equity (9M 2026, annualised).
- Equity and assets
- Equity is 74% of its assets; the rest is owed to others.
- Price and earnings
- No P/E: the exchange publishes none when the last four quarters show a loss.
Size and price
As of Nov 17, 2026.
market cap · NT$10.3B
P/E · market median 16.1
dividend yield
Revenue, month by month
Taiwanese companies report revenue every month, by the 10th of the next.
revenue in October 2026
on the same month last year
this year so far, on last year
The latest report
9M 2026, year to date, consolidated.
- Revenue
- NT$27M
- Operating income-3,485% of revenue
- −NT$954M
- Net incometo shareholders
- −NT$885M
- Earnings per share
- −NT$6.73
- Total assets
- NT$2.5B
- Equity
- NT$1.9B
- Book value per share
- NT$9.23
Also in biotech and medical
The largest listed peers in Taiwan, by market cap.
- 6446.TW PharmaEssentia
- $16.6B
- 6919.TW Caliway
- $3.2B
- 7799.TW HNMC
- $2.2B
- 6949.TW Pell BMT
- $2.0B
- 6472.TW Bora
- $1.4B
- 1795.TW Lotus Pharm
- $1.1B
Source: Taiwan Stock Exchange and Taipei Exchange OpenAPI, published on data.gov.tw under the Open Government Data License, version 1.0. Ryufin computed the ratios, market cap and growth rates from that data. US dollar figures use the BIS TWD/USD rate. Prices are end of day. Price history on Ryufin starts on Sep 24, 2026 and grows by one close each trading day.